Welcome to our dedicated page for Iwallet SEC filings (Ticker: IWAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. regulatory filings for iWallet Corporation (IWAL), a company that describes itself as developing secure personal and security-oriented accessories. While no specific SEC filings are included in the provided data, investors commonly review documents such as annual and quarterly reports, current reports, and insider transaction filings to understand a company’s operations and governance.
For a business like iWallet, which publicly emphasizes product development in smart wallets and security-focused accessories, regulatory filings can offer structured information on its business description, risk factors, and capital structure. Filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q, when available, typically include narrative sections on products, markets, and material risks, along with financial statements. Current reports on Form 8-K, if filed, may describe significant events such as material agreements, product-related developments, or changes in corporate structure.
Insider transaction reports on Form 4, when present, can show purchases or sales of the company’s securities by officers, directors, or significant shareholders. Proxy materials, such as those filed on Schedule 14A, can provide additional detail on governance, compensation, and matters submitted to shareholders.
On Stock Titan, iWallet-related filings, when available from EDGAR, can be paired with AI-powered summaries that highlight key sections and help explain the structure and terminology of each document. This can assist readers who want to understand how iWallet describes its business, products, and risks in formal regulatory disclosures, complementing the narrative provided in its news releases.
iWallet Corp filed its Q3 2025 10‑Q, reporting $0 revenue and a net loss of $185,511 for the quarter. For the nine months, net loss was $381,065.
Operating expenses rose sharply to $181,874 in Q3, driven by R&D of $161,882 as the company develops its new product. Cash was $229 at September 30, 2025, with a working capital deficit of $693,849 and current liabilities of $694,078, including $260,000 in convertible debentures and $315,382 in accrued interest. Management states there is substantial doubt about the company’s ability to continue as a going concern.
To manage obligations, the company converted debt and payables into equity, issuing 5,000,000 shares in April 2025 for note conversion and 3,600,000 shares in July/August 2025 to settle accounts payable. A subsequent event on October 8, 2025 issued 20,000,000 shares to the CEO for services, valued at $600,000. Shares outstanding were 106,419,419 as of November 13, 2025.